Organon & Co. ( OGN ) Nowojorska Giełda Papierów Wartościowych

Cena: 9.44 ( 1.67% )

Aktualizacja 08-22 21:59
Nowojorska Giełda Papierów Wartościowych
Branża: Drug Manufacturers - General
Finanse
Rachunek zysków i strat
Bilans
Przepływy pieniężne
Prognozy
Statystyki
Dywidendy
Rekomendacje
Modele wyceny
Wskaźniki
Analiza techniczna

Notowania:

Opis firmy:

Organon & Co., firma zajmująca się opieką zdrowotną, rozwija i dostarcza rozwiązania zdrowotne za pośrednictwem portfela terapii na receptę w Stanach Zjednoczonych i na arenie międzynarodowej. Portfolio zdrowia kobiet obejmuje marki antykoncepcyjne i płodności, takie jak Nexplanon/Implanon, długo działający odwracalny środek antykoncepcyjny. Portfolio biosimilars firmy składa się z trzech produktów immunologicznych, takich jak Brenzys, Renflexis i Hadlima, a także dwa produkty onkologiczne, w tym OnTruzant i Aybintio. Oferuje również produkty sercowo-naczyniowe, składające się z kilku leków modyfikujących cholesterol pod markami Zetii, Ezetrol, Vytorin, Inegy, Rosuzet i Zocor; Cozaar i Hyzaar do leczenia nadciśnienia; Produkty oddechowe dla różnych metod leczenia w celu kontroli i zapobiegania objawom spowodowanymi przez astmę pod nazwami marek Singulair, Dulera, Zenhale i Asmanex; oraz Singulair, Nasonex, Clarinex i Aerius w leczeniu sezonowego alergicznego zapalenia nosa. Ponadto firma zapewnia produkty dermatologiczne pod marką Diprosone i Elocon; Portfolio zdrowia kości, w tym nazwa marki Fosamax; Produkty nieopioidowe zarządzania bólem pod nazwami marek Arcoxia, Diprospan i Celestone; ProsCAR w leczeniu objawowego łagodnego przerostu prostaty; i propecia do leczenia męskiego wzoru wypadania włosów. Firma sprzedaje swoje produkty przede wszystkim hurtownikom i detalistom, szpitalom i agencjom rządowym, a także zarządzanym świadczeniodawcom, takich jak organizacje zajmujące się utrzymaniem zdrowia, menedżerowie ds. Świadczeń apteki i inne instytucje. Organon & Co. został zarejestrowany w 2020 r. I ma siedzibę w Jersey City, New Jersey.

Informacje o spółce:
Sektor: Zdrowie
Branża: Drug Manufacturers - General
Zatrudnienie: 10 000
Giełda: Nowojorska Giełda Papierów Wartościowych
Ilość akcji w obrocie: 99.8941
Ilość akcji: Brak danych
Debiut giełdowy: 2021-05-14
WWW: https://www.organon.com
CEO: Mr. Kevin Ali
Adres: 30 Hudson Street
Siedziba: 07302 Jersey City
ISIN: US68622V1061
Wskaźniki finansowe
Kapitalizacja (USD) 2 452 779 210
Aktywa: 12 752 000 000
Cena: 9.44
Wskaźnik Altman Z-Score: 1.4
Słaby (wysokie ryzyko bankructwa)
Dywidenda: 1
P/E: 3.5
Ilość akcji w obrocie: 100%
Średni wolumen: 4 303 948
Ilość akcji 259 966 000
Wskaźniki finansowe
Przychody TTM 6 409 000 000
Zobowiązania: 12 259 000 000
Przedział 52 tyg.: 8.01 - 23.1
Piotroski F-Score: 4
Umiarkowany (średnia jakość finansowa)
EPS: 2.7
P/E branży: 23.8
Beta: 0.796
Raport okresowy: 2025-10-30
WWW: https://www.organon.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Mr. Kevin Ali Chief Executive Officer & Director 3 822 254 1960
Mr. Matthew M. Walsh Executive Vice President & Chief Financial Officer 1 809 777 1967
Mr. Joseph T. Morrissey Jr. Executive Vice President and Head of Manufacturing & Supply 1 535 013 1965
Mr. Kirke Weaver Executive Vice President, General Counsel & Corporate Secretary 1 441 125 1974
Ms. Susanne Gabriele Fiedler Executive Vice President & Chief Commercial Officer 1 375 135 1968
Ms. Jennifer Halchak Head of Investor Relations 0 0
Ms. Susan O'Neal Chief Ethics & Compliance Officer 0 0
Mr. Daniel Karp Chief Business Development Officer 0 1978
Ms. Rebecca Lowell Edwards Chief Communications Officer 0 0
Ms. Rachel A. Stahler Executive Vice President & Chief Information Officer 0 1976
Lista ETF z ekspozycją na akcje Organon & Co.
Symbol ETF Ilość akcji Wartość
IJR 16 063 472 155 815 679
VB 6 348 203 61 450 605
SCYB 4 082 000 3 752 422
VBR 4 052 966 39 232 710
HIHC.SW 3 714 832 29 282 567
EUNW.DE 3 450 870 29 282 567
IHYG.L 3 450 870 29 282 567
IHYG.MI 3 450 870 29 282 567
HIGH.L 3 450 870 29 282 567
SHYG.L 3 450 218 25 330 592
EHYG.L 3 218 707 23 630 894
HYGU.L 3 018 821 29 282 567
AYE2.DE 2 784 836 23 630 894
EHYD.AS 2 784 836 23 630 894
EHYA.AS 2 784 836 23 630 894
XHY.TO 2 675 000 3 397 796
JPIE 2 670 000 2 527 179
IJS 2 532 861 24 568 753
JPIE 2 470 000 2 136 835
SPSM 2 241 787 22 563 338
FXH 1 638 964 16 094 626
SLYV 1 479 763 15 049 345
JCPB 1 475 000 1 276 045
DES 1 402 746 13 606 636
SCHA 1 231 005 12 143 996
VYM 993 881 9 620 768
IWR 960 032 9 312 310
OUSM 942 637 9 143 578
BBHY 926 000 876 467
DIV 901 210 8 741 737
VIOO 860 586 8 330 472
VHT 805 561 7 797 830
GHYG.L 747 108 5 485 072
DHYG.L 745 892 5 476 142
IHE 726 892 7 050 851
BINC 724 785 7 030 416
BBHY 724 000 682 716
SIHY 700 000 627 189
JCPB 700 000 662 556
HYLC.SW 695 845 5 485 072
DHYC.SW 694 712 5 476 142
SCHM 692 897 6 880 803
RWJ 677 224 6 799 328
DHYG.L 660 349 4 848 109
HYLE.DE 646 401 5 485 072
UEEF.DE 645 348 5 476 142
FNDX 617 936 6 165 864
DHYC.SW 615 039 4 848 109
DFAS 596 679 5 787 786
IWD 591 206 5 734 697
UEEF.DE 571 336 4 848 109
HYLA.L 565 471 5 485 072
IBC9.DE 565 471 4 798 341
HYLD.L 565 471 5 485 072
IGHY.L 565 471 4 151 541
DHYE.AS 564 551 4 790 529
DHYD.AS 564 551 5 476 142
DHYA.L 564 551 5 476 142
XPH 554 689 5 603 988
VIOV 525 897 5 090 682
AVSC 507 958 5 099 898
DHYA.L 499 805 4 848 109
DHYD.AS 499 805 4 848 109
DHYE.AS 499 805 4 241 126
BINC 461 831 4 479 756
IWS 394 038 3 822 167
IUS3.DE 385 390 3 270 250
IDP6.L 385 390 3 738 283
ISP6.L 385 390 2 829 432
BBHY 381 000 341 117
BINC 372 649 3 614 692
DFAC 338 260 3 281 122
HYSD.L 332 523 2 441 294
ITOT 320 511 3 108 956
FSYD 318 000 274 611
HYSD.L 295 401 2 168 754
FNX 255 747 2 511 435
GHYB 252 000 378 460
GHYB 252 000 242 563
HYUS.L 251 680 2 441 294
HYUS.SW 251 680 2 441 294
PSCH 249 236 2 502 329
USVM 240 071 2 328 688
NEAR 229 000 219 792
HYUS.L 223 583 2 168 754
HYUS.SW 223 583 2 168 754
FLQM 216 550 2 174 162
PRF 206 515 2 073 410
IWB 197 755 1 918 222
FMDE 188 844 1 882 774
IHHG.L 170 922 1 254 867
DHYG.L 170 080 1 248 680
DHYG.L 168 728 1 238 753
EZM 164 051 1 591 294
SCHB 163 063 1 630 986
DHYC.SW 158 410 1 248 680
FLQL 157 941 1 585 727
DHYC.SW 157 150 1 238 753
FSMD 156 392 1 559 228
DHS 152 938 1 483 498
IYH 150 974 1 464 444
CSB 150 857 1 463 312
ZPRV.DE 149 961 1 148 485
USSC.L 149 961 1 311 505
IHYE.L 147 883 1 254 867
IBC2.DE 147 883 1 254 867
UEEF.DE 147 154 1 248 680
UEEF.DE 145 984 1 238 753
CUS1.L 133 787 982 226
CSUSS.MI 133 787 1 135 254
CUSS.L 133 787 1 297 730
SXRG.DE 133 787 1 135 254
VONV 131 093 1 268 980
IHYU.L 129 368 1 254 867
IS0R.DE 129 368 1 097 757
IHYU.MI 129 368 1 097 757
SHYU.L 129 368 949 783
IHYA.L 129 368 1 254 867
DHYE.AS 128 730 1 092 346
DHYD.AS 128 730 1 248 680
DHYA.L 128 730 1 248 680
DHYA.L 127 707 1 238 753
DHYD.AS 127 707 1 238 753
DHYE.AS 127 707 1 083 661
FNK 121 786 1 195 938
BBMC 116 356 1 128 653
ESML 112 565 1 130 152
FHLC 109 540 1 092 113
HYSD.L 104 619 768 086
JHSC 104 465 909 890
IJR.AX 91 762 1 425 975
AFLG 91 161 895 201
VFVA 89 730 868 586
PPH 88 909 862 417
IHHG.L 84 594 621 070
BSMC 82 312 798 426
HYUS.L 79 184 768 086
HYUS.SW 79 184 768 086
HYSD.L 77 565 569 464
ONEY 77 280 789 567
IHYE.L 73 191 621 070
IBC2.DE 73 191 621 070
FSYD 72 000 67 861
IWV 70 091 679 878
GHYG.L 69 804 512 483
HYLC.SW 65 015 512 483
IHYA.L 64 028 621 070
IHYU.MI 64 028 543 312
SHYU.L 64 028 470 075
IS0R.DE 64 028 543 312
IHYU.L 64 028 621 070
GHYG.L 62 640 459 889
IS3K.DE 61 721 523 739
SDHG.L 61 721 453 141
SDHY.L 61 721 598 696
SDHA.L 61 721 598 696
EH1Y.DE 61 396 520 977
SMMD 60 616 608 584
HYLE.DE 60 395 512 483
HYUS.L 58 708 569 464
HYUS.SW 58 708 569 464
HYLC.SW 58 342 459 889
ESGV 56 865 550 453
EQAL 56 735 569 619
HYLE.DE 54 197 459 889
HYLD.L 52 833 512 483
IGHY.L 52 833 387 888
IBC9.DE 52 833 448 320
HYLA.L 52 833 512 483
TILT 50 352 488 414
DFAU 49 641 481 517
BRLN 49 637 47 775
HYLA.L 47 411 459 889
IBC9.DE 47 411 402 311
HYLD.L 47 411 459 889
IGHY.L 47 411 348 081
SPTM 47 237 475 072
VVL.TO 47 151 622 787
GHYS.L 46 602 342 139
GHYC.SW 43 852 345 666
VONE 40 310 390 200
GHYG.L 39 144 287 385
QVMS 38 272 384 250
AVUS 37 779 379 301
IHHG.L 37 280 273 700
HYLC.SW 36 458 287 385
JVAL 33 897 328 800
HYLE.DE 33 868 287 385
IHHG.L 32 409 237 940
IBC2.DE 32 255 273 700
IHYE.L 32 255 273 700
JPME 29 825 289 302
HYLA.L 29 627 287 385
IBC9.DE 29 627 251 405
HYLD.L 29 627 287 385
IGHY.L 29 627 217 516
FNDB 28 713 286 370
BINC 28 398 275 459
SHYU.L 28 217 207 158
IHYA.L 28 217 273 700
IHYU.L 28 217 273 700
IHYU.MI 28 217 239 433
IS0R.DE 28 217 239 433
IHYE.L 28 041 237 940
IBC2.DE 28 041 237 940
FTXH 27 775 272 750
BINC 25 640 248 703
SHYU.L 24 530 180 092
IHYA.L 24 530 237 940
IHYU.L 24 530 237 940
IHYU.MI 24 530 208 150
IS0R.DE 24 530 208 150
ROSC 24 151 242 476
DTD 23 008 223 177
FAB 21 677 212 868
XJR 20 544 206 261
VTHR 20 390 197 375
PILL 20 315 197 055
VOOM.DE 20 169 176 052
ELLE.L 20 169 200 990
GEND.L 20 169 152 309
DIVB 20 062 201 422
DHS.L 19 805 197 059
WTEU.DE 19 805 197 059
DHSD.L 19 805 197 059
WTD9.DE 19 805 197 059
WTDY.DE 19 805 197 059
DHSP.L 19 805 197 059
DHSG.L 19 805 197 059
DHSA.L 19 805 197 059
DHSF.MI 19 805 197 059
LSEQ 19 550 196 282
SCHK 19 224 192 327
SQLV 18 663 187 376
DCOR 18 613 180 546
JPUS 16 496 160 011
SMLV 16 385 166 325
ISCB 11 942 115 841
IYY 11 164 108 291
XUU.TO 10 690 148 266
VLU 10 666 107 690
GHYC.SW 9 854 77 672
HEJD 9 162 88 871
XSMC.TO 9 156 126 987
DEW 8 985 87 154
XSMH.TO 8 469 117 462
STXK 8 279 80 306
DXUV 6 746 65 436
AFMC 6 548 64 301
CBUG.DE 6 200 52 610
EWSA.AS 6 200 60 139
MFUS 5 881 59 045
VPLS 5 000 4 802
SAA 4 792 46 482
FRUE.L 4 564 45 822
FLXU.DE 4 564 45 822
FLXU.L 4 564 45 822
GHYS.L 4 489 32 955
SEIV 3 900 0
GVUS 3 765 37 311
IHHY.AX 3 606 629 926
V3AA.L 3 063 29 649
V3AB.L 3 063 22 468
V3AL.L 3 063 29 649
SPGM 2 970 29 890
CSA 2 671 30 022
JUST 2 650 26 261
GHYS.L 2 454 18 018
GHYC.SW 2 253 17 757
ESIX 1 989 20 083
XBAL.TO 1 785 24 764
USUE.DE 1 689 16 961
USFM.L 1 689 16 961
XUH.TO 1 579 15 848
STXV 1 109 10 757
IHHY.AX 1 034 144 679
R1VL.L 1 006 9 758
GHYC.SW 938 7 397
GHYS.L 935 6 864
GVLU 934 0
CHGX 923 24 214
XTR.TO 912 114 337
CSF 829 9 317
GHYC.SW 490 3 858
GHYS.L 488 3 580
VALQ 394 250 748
MMTM 170 1 702
EUHI.DE 137 1 351 744
AVIE 130 1 305
XTR.TO 64 641
6PSA.DE 0 122 105
PXS.TO 0 9 358
PSWD.DE 0 11 711
USML.L 0 351 350
PSRF.L 0 10 585 519
PSRW.L 0 1 015 263
PRUS.L 0 139 358
CDX -54 331 -527 013
Wiadomości dla Organon & Co.
Tytuł Treść Źródło Aktualizacja Link
Shareholders Alert: Investigation Into Organon & Co. (OGN) - Contact Levi & Korsinsky to Protect Your Rights NEW YORK, NY / ACCESS Newswire / May 16, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Organon & Co. ("Organon & Co.") (NYSE:OGN) concerning possible violations of federal securities laws. On May 1, 2025, Organon reported mixed Q1 FY25 results, missing expectations on revenue decline of 7% y/y to $1.51B. accessnewswire.com 2025-05-16 14:15:00 Czytaj oryginał (ang.)
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Organon & Co. (OGN) and Encourages Investors to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Organon & Co. ("Organon" or "the Company") (NYSE:OGN). Investors who purchased Organon securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/OGN. accessnewswire.com 2025-05-16 14:00:00 Czytaj oryginał (ang.)
Levi & Korsinsky Launches Fraud Investigation on Behalf of Organon & Co. (OGN) Shareholders NEW YORK, NY / ACCESS Newswire / May 15, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Organon & Co. ("Organon & Co.") (NYSE:OGN) concerning possible violations of federal securities laws. On May 1, 2025, Organon reported mixed Q1 FY25 results, missing expectations on revenue decline of 7% y/y to $1.51B. accessnewswire.com 2025-05-15 14:30:00 Czytaj oryginał (ang.)
Organon & Co. (OGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / May 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Organon & Co. ("Organon" or "the Company") (NYSE: OGN). Investors who purchased Organon securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/OGN. accessnewswire.com 2025-05-15 14:00:00 Czytaj oryginał (ang.)
Levi & Korsinsky Investigates Organon & Co. (OGN) Over Possible Securities Fraud NEW YORK, NY / ACCESS Newswire / May 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Organon & Co. ("Organon & Co.") (NYSE:OGN) concerning possible violations of federal securities laws. On May 1, 2025, Organon reported mixed Q1 FY25 results, missing expectations on revenue decline of 7% y/y to $1.51B. accessnewswire.com 2025-05-15 01:20:00 Czytaj oryginał (ang.)
Levi & Korsinsky Investigates Organon & Co. (OGN) Over Possible Securities Fraud NEW YORK, NY / ACCESS Newswire / May 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Organon & Co. ("Organon & Co.") (NYSE:OGN) concerning possible violations of federal securities laws. On May 1, 2025, Organon reported mixed Q1 FY25 results, missing expectations on revenue decline of 7% y/y to $1.51B. accessnewswire.com 2025-05-14 14:15:00 Czytaj oryginał (ang.)
Bronstein, Gewirtz & Grossman, LLC Is Investigating Organon & Co. (OGN) And Encourages Investors to Connect NEW YORK CITY, NY / ACCESS Newswire / May 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Organon & Co. ("Organon" or "the Company") (NYSE: OGN). Investors who purchased Organon securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/OGN. accessnewswire.com 2025-05-14 14:00:00 Czytaj oryginał (ang.)
Organon & Co. (OGN) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights NEW YORK, NY / ACCESS Newswire / May 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Organon & Co. ("Organon & Co.") (NYSE:OGN) concerning possible violations of federal securities laws. On May 1, 2025, Organon reported mixed Q1 FY25 results, missing expectations on revenue decline of 7% y/y to $1.51B. accessnewswire.com 2025-05-13 14:15:00 Czytaj oryginał (ang.)
Organon & Co: Cost Takeout Catalysts, Initiate Strong Buy Initiate Strong Buy on Organon & Co. with $26.4 PT, driven by cost savings, Nexplanon momentum, and biosimilars diversification offsetting Established Brands LOE. Forecasted EPS of $4.00 (FY25; +20.1% Y/Y) and $4.40 (FY26; +10.0%), well above consensus, supported by operational leverage and dividend cut for deleveraging. Transformational cost savings of >$200M by FY25 and $275M by FY26, driving margin expansion and multi-year EPS acceleration. seekingalpha.com 2025-05-12 15:47:04 Czytaj oryginał (ang.)
Organon & Co. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - OGN NEW YORK, NY / ACCESS Newswire / May 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Organon & Co. ("Organon & Co.") (NYSE:OGN) concerning possible violations of federal securities laws. On May 1, 2025, Organon reported mixed Q1 FY25 results, missing expectations on revenue decline of 7% y/y to $1.51B. accessnewswire.com 2025-05-12 14:15:00 Czytaj oryginał (ang.)
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Organon & Co. (OGN) and Encourages Investors to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / May 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Organon & Co. ("Organon" or "the Company") (NYSE: OGN). Investors who purchased Organon securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/OGN. accessnewswire.com 2025-05-12 14:00:00 Czytaj oryginał (ang.)
Shareholders that lost money on Organon & Co.(OGN) should contact Levi & Korsinsky about Securities Fraud Investigation - OGN NEW YORK, NY / ACCESS Newswire / May 11, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Organon & Co. ("Organon & Co.") (NYSE:OGN) concerning possible violations of federal securities laws. On May 1, 2025, Organon reported mixed Q1 FY25 results, missing expectations on revenue decline of 7% y/y to $1.51B. accessnewswire.com 2025-05-11 15:00:00 Czytaj oryginał (ang.)
Bronstein, Gewirtz & Grossman, LLC Is Investigating Organon & Co. (OGN) And Encourages Stockholders to Connect NEW YORK CITY, NY / ACCESS Newswire / May 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Organon & Co. ("Organon" or "the Company") (NYSE: OGN). Investors who purchased Organon securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/OGN. accessnewswire.com 2025-05-11 14:00:00 Czytaj oryginał (ang.)
Organon & Co. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - OGN NEW YORK, NY / ACCESS Newswire / May 10, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Organon & Co. ("Organon & Co.") (NYSE:OGN) concerning possible violations of federal securities laws. On May 1, 2025, Organon reported mixed Q1 FY25 results, missing expectations on revenue decline of 7% y/y to $1.51B. accessnewswire.com 2025-05-10 22:01:00 Czytaj oryginał (ang.)
OGN INVESTIGATION NOTICE: Investigation Launched into Organon & Co. and Attorneys Encourage Investors with Substantial Losses or Witnesses with Relevant Information to Contact Law Firm SAN DIEGO , May 10, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Organon & Co. (NYSE: OGN) focused on whether Organon as well as certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors. If you have information that could assist in the Organon investigation or if you are an Organon investor who suffered a loss and would like to learn more, you can provide your information here: https://www.rgrdlaw.com/cases-organon-co-investigation-ogn.html You can also contact attorneys J.C. prnewswire.com 2025-05-10 14:40:00 Czytaj oryginał (ang.)
OGN STOCK ALERT: Levi & Korsinsky Notifies Organon & Co. Investors of an Ongoing Investigation NEW YORK, NY / ACCESS Newswire / May 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Organon & Co. ("Organon & Co.") (NYSE:OGN) concerning possible violations of federal securities laws. On May 1, 2025, Organon reported mixed Q1 FY25 results, missing expectations on revenue decline of 7% y/y to $1.51B. accessnewswire.com 2025-05-09 14:30:00 Czytaj oryginał (ang.)
Organon & Co. (OGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / May 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Organon & Co. ("Organon" or "the Company") (NYSE:OGN). Investors who purchased Organon securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/OGN. accessnewswire.com 2025-05-09 14:00:00 Czytaj oryginał (ang.)
OGN STOCK ALERT: Levi & Korsinsky Notifies Organon & Co. Investors of an Ongoing Investigation NEW YORK, NY / ACCESS Newswire / May 8, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Organon & Co. ("Organon & Co.") (NYSE:OGN) concerning possible violations of federal securities laws. On May 1, 2025, Organon reported mixed Q1 FY25 results, missing expectations on revenue decline of 7% y/y to $1.51B. accessnewswire.com 2025-05-09 01:20:00 Czytaj oryginał (ang.)
ORGANON ALERT: Bragar Eagel & Squire, P.C. is Investigating Organon & Co. on Behalf of Organon Stockholders and Encourages Investors to Contact the Firm NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Organon & Co. (“Organon” or the “Company”) (NYSE:OGN) on behalf of Organon stockholders. Our investigation concerns whether Organon has violated the federal securities laws and/or engaged in other unlawful business practices. globenewswire.com 2025-05-09 01:00:00 Czytaj oryginał (ang.)
Organon: Management Slashes Dividend - This Feels Disastrous Organon's Q1 2025 earnings report showed significant declines across key financial metrics, leading to a drastic 30% drop in share price following a >90% dividend cut. The company's revenue shrinkage is primarily due to declining sales in its Established Brands division, exacerbated by the patent expiry of key drugs. Management's rationale for cutting the dividend to manage debt and pursue M&A opportunities appears flawed, as it fails to address core financial issues. seekingalpha.com 2025-05-08 15:08:06 Czytaj oryginał (ang.)
High-Yield Healthcare: 3 Stocks With Strong Dividends When it comes to dividend performers, healthcare usually takes a backseat to options like REITs and energy stocks. However, the sector's resilience, driven by aging populations and consistent demand for medical services, makes it an underrated source of steady income. marketbeat.com 2025-02-16 09:16:00 Czytaj oryginał (ang.)
Organon & Co. (OGN) Q4 2024 Earnings Call Transcript Organon & Co. (NYSE:OGN ) Q4 2024 Earnings Conference Call February 13, 2025 8:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO Juan Camilo Arjona Ferreira - Head of R&D Matt Walsh - CFO Conference Call Participants Terence Flynn - Morgan Stanley Michael Nedelcovych - TD Cowen Ethan Brown - JPMorgan David Amsellem - Piper Sandler Balaji Prasad - Barclays Jason Gerberry - Bank of America Umer Raffat - Evercore ISI Operator Thank you for standing by. My name is Celine and I will be your conference operator today. seekingalpha.com 2025-02-13 14:47:18 Czytaj oryginał (ang.)
Organon (OGN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates The headline numbers for Organon (OGN) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com 2025-02-13 13:31:15 Czytaj oryginał (ang.)
Organon (OGN) Q4 Earnings and Revenues Beat Estimates Organon (OGN) came out with quarterly earnings of $0.90 per share, beating the Zacks Consensus Estimate of $0.86 per share. This compares to earnings of $0.88 per share a year ago. zacks.com 2025-02-13 11:46:13 Czytaj oryginał (ang.)
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2024 JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announces Q4 2024 and Full Year 2024 earnings results, ending December 31, 2024. businesswire.com 2025-02-13 09:30:00 Czytaj oryginał (ang.)
Why Organon (OGN) Dipped More Than Broader Market Today Organon (OGN) concluded the recent trading session at $14.62, signifying a -1.81% move from its prior day's close. zacks.com 2025-02-07 20:50:17 Czytaj oryginał (ang.)
Organon (OGN) Rises Higher Than Market: Key Facts The latest trading day saw Organon (OGN) settling at $15.97, representing a +0.82% change from its previous close. zacks.com 2025-01-30 20:56:30 Czytaj oryginał (ang.)
Organon (OGN) Increases Despite Market Slip: Here's What You Need to Know Organon (OGN) closed at $16.26 in the latest trading session, marking a +1.82% move from the prior day. zacks.com 2025-01-27 21:06:20 Czytaj oryginał (ang.)
Organon To Report Fourth Quarter and Full Year 2024 Results and Host Conference Call on February 13, 2025 JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon To Report Fourth Quarter and Full Year 2024 Results and Host Conference Call on February 13, 2025. businesswire.com 2025-01-23 09:30:00 Czytaj oryginał (ang.)
Organon (OGN) Surpasses Market Returns: Some Facts Worth Knowing Organon (OGN) closed the most recent trading day at $15.88, moving +0.89% from the previous trading session. zacks.com 2025-01-21 21:05:28 Czytaj oryginał (ang.)
Organon: A Tricky 2025 Awaits, But I'm Happy With A >7% Dividend Yield Organon has faced significant price volatility and underperformance since its spin-off from Merck, with shares down ~50% since 2021. Key products like Nexplanon and VTAMA are crucial for future growth, but uncertainties and competition pose significant risks to revenue projections. Organon's high debt and interest payments are significant concerns, despite low P/S and P/E ratios suggesting undervaluation, and a strong dividend yield. seekingalpha.com 2025-01-17 15:03:31 Czytaj oryginał (ang.)
Organon & Co. (OGN) JPMorgan Annual Healthcare Conference - (Transcript) Organon & Co. (NYSE:OGN ) JPMorgan Annual Healthcare Conference Call January 13, 2025 6:45 PM ET Company Participants Kevin Ali - Chief Executive Officer Matthew Walsh - Chief Financial Officer Conference Call Participants Chris Schott - JPMorgan Chris Schott Good afternoon, everybody. I'm Chris Schott from JPMorgan and it's my pleasure to be hosting this fireside chat with the Organon management team. seekingalpha.com 2025-01-13 23:38:25 Czytaj oryginał (ang.)
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store. zacks.com 2025-01-01 12:01:20 Czytaj oryginał (ang.)
Want $2,000 in Annual Dividends? Invest $11,000 in Each of These 3 Stocks. Investing in dividend stocks can be an excellent way to boost your income each year. But the challenge can be generating a good return while keeping your risk low. fool.com 2025-01-01 09:55:00 Czytaj oryginał (ang.)
Organon (OGN) Ascends While Market Falls: Some Facts to Note Organon (OGN) closed at $15.06 in the latest trading session, marking a +0.74% move from the prior day. zacks.com 2024-12-27 20:56:22 Czytaj oryginał (ang.)
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects. zacks.com 2024-12-20 12:00:38 Czytaj oryginał (ang.)
Organon To Present at the 43rd Annual J.P. Morgan Healthcare Conference JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon CEO Kevin Ali and CFO Matthew Walsh to present in a fireside chat at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13th. businesswire.com 2024-12-19 09:30:00 Czytaj oryginał (ang.)
Organon price target raised to $20 from $19 at Goldman Sachs Goldman Sachs raised the firm's price target on Organon to $20 from $19 and keeps a Neutral rating on the shares. The firm cites the company's announced FDA approval of VTAMA for the topical treatment of atopic dermatitis, or AD, in adults and pediatric patients 2 years of age and older. VTAMA's AD approval addresses multiple unmet needs in the atopic dermatitis market previously demonstrated by their Phase 3 results, though the firm expects successful launch will require a heightened level of investment in sales/marketing support given the primary care dimensions of the AD market, the analyst tells investors in a research note. https://thefly.com 2024-12-17 19:42:00 Czytaj oryginał (ang.)
Final Trades: Amazon, American Express and Organon The CNBC 'Halftime Report' Investment Committee give their top stocks to watch for the second half. youtube.com 2024-12-10 15:40:22 Czytaj oryginał (ang.)
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. zacks.com 2024-12-09 12:00:39 Czytaj oryginał (ang.)
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store. zacks.com 2024-11-26 12:00:31 Czytaj oryginał (ang.)
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. zacks.com 2024-11-15 12:01:17 Czytaj oryginał (ang.)
Organon: 7% Yield, 4x P/E, Big Upside Potential Organon is a deep value stock with a high 7.2% yield, supported by a diversified portfolio in women's health, biosimilars, and established pharmaceuticals. Despite stock price volatility, OGN has shown steady performance with growth in adjusted EBITDA and free cash flow. The acquisition of Dermavant and its promising treatment VTAMA for psoriasis and atopic dermatitis could be transformative, expanding OGN's reach into high-demand areas. seekingalpha.com 2024-11-14 14:42:51 Czytaj oryginał (ang.)
Organon: Certainly A Risky Bet, But Looks Increasingly Compelling (Upgrade) In this update, I'll focus on Organon's Q3 2024 results, earnings adjustments and segment performance, as well as the acquisition of Dermavant. Organon reported solid Q3 2024 results with 4% revenue growth, driven by strong volume growth more than offsetting pricing weakness and currency headwinds. The $1.2 billion Dermavant acquisition appears strategically acceptable but carries significant risks due to market competition and OGN's high debt. seekingalpha.com 2024-11-13 10:30:00 Czytaj oryginał (ang.)
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store. zacks.com 2024-11-04 12:00:21 Czytaj oryginał (ang.)
Organon & Co. (OGN) Q3 2024 Earnings Call Transcript Organon & Co. (NYSE:OGN ) Q3 2024 Earnings Call Transcript October 31, 2024 8:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO Juan Camilo Arjona Ferreira - Head of R&D Matt Walsh - CFO Conference Call Participants Balaji Prasad - Barclays David Amsellem - Piper Sandler Jason Gerberry - Bank of America Umer Raffat - Evercore ISI Operator Thank you for standing by. My name is Mandeep and I'll be your operator today. seekingalpha.com 2024-10-31 14:28:12 Czytaj oryginał (ang.)
Organon (OGN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates The headline numbers for Organon (OGN) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com 2024-10-31 13:30:16 Czytaj oryginał (ang.)
Organon (OGN) Q3 Earnings and Revenues Beat Estimates Organon (OGN) came out with quarterly earnings of $0.87 per share, beating the Zacks Consensus Estimate of $0.85 per share. This compares to earnings of $0.87 per share a year ago. zacks.com 2024-10-31 11:46:11 Czytaj oryginał (ang.)
Organon Reports Results for the Third Quarter Ended September 30, 2024 JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon Reports Q3 2024 Earnings. businesswire.com 2024-10-31 09:30:00 Czytaj oryginał (ang.)
Ahead of Organon (OGN) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics Evaluate the expected performance of Organon (OGN) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight. zacks.com 2024-10-28 12:21:36 Czytaj oryginał (ang.)
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1% JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon expands dermatology capabilities through completion of Dermavant acquisition, including nonbiologic, non-steroidal VTAMA Cream, 1%. businesswire.com 2024-10-28 11:25:00 Czytaj oryginał (ang.)
Earnings Preview: Organon (OGN) Q3 Earnings Expected to Decline Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com 2024-10-24 15:06:01 Czytaj oryginał (ang.)